Motus GI (MOTS) Receives Buy Rating from Oppenheimer
A number of other brokerages have also recently issued reports on MOTS. EuroPacific Canada started coverage on shares of Motus GI in a research note on Thursday, May 31st. They issued a buy rating and a $12.00 price objective for the company. Piper Jaffray Companies restated an overweight rating and issued a $8.00 price objective on shares of Motus GI in a research note on Tuesday, August 14th. ValuEngine upgraded shares of Motus GI from a hold rating to a buy rating in a research report on Wednesday, July 4th. Dougherty & Co assumed coverage on shares of Motus GI in a research report on Tuesday, August 28th. They set a buy rating and a $8.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Motus GI from a sell rating to a hold rating in a research report on Saturday, August 18th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $10.50.
Shares of MOTS stock opened at $5.18 on Tuesday. Motus GI has a 52-week low of $3.75 and a 52-week high of $10.66.
Several institutional investors have recently made changes to their positions in the stock. IPG Investment Advisors LLC acquired a new stake in shares of Motus GI during the 2nd quarter worth about $106,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Motus GI during the 2nd quarter worth about $113,000. Highbridge Capital Management LLC acquired a new stake in shares of Motus GI during the 1st quarter worth about $896,000. Finally, Hilltop Holdings Inc. acquired a new stake in shares of Motus GI during the 1st quarter worth about $502,000. Institutional investors and hedge funds own 21.61% of the company’s stock.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Further Reading: Earnings Per Share (EPS)
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.